Obese Patients With or Without Comorbidities (RIO-North America)
NCT ID: NCT00029861
Last Updated: 2009-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
3045 participants
INTERVENTIONAL
2001-08-31
2004-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)
NCT00386061
Obese Patients With Type 2 Diabetes
NCT00029848
Obese Patients With Untreated Dyslipidemias
NCT00029835
Japanese Dose-Response Study of Rimonabant in Obese Patients
NCT00459004
Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)
NCT00325546
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rimonabant (SR141716)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI (Body Mass Index) of 30 or greater in patients with or without comorbidities, or BMI greater than 27 in patients with treated or untreated hypertension and/or treated or untreated dyslipidemia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
sanofi-aventis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ICD CSD
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Radiant Research
Birmingham, Alabama, United States
Radiant Research
Phoenix, Arizona, United States
East Bay Clinical Trial Center
Concord, California, United States
Feighner Research Institute
San Diego, California, United States
Scripps Clinic
San Diego, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Ranch View Family Medicine
Highlands Ranch, Colorado, United States
Longmont Medical Research Network
Longmont, Colorado, United States
Health Core, Inc.
Newark, Delaware, United States
George Washington Univ. Wieght Mmgt Program
Washington D.C., District of Columbia, United States
Miami Research Associates
Miami, Florida, United States
Anchor Research Center
Naples, Florida, United States
Central Florida Clinical Solutions
Ocoee, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
Palm Beach Research Center
West Palm Beach, Florida, United States
Medical Dietetics, Inc.
Atlanta, Georgia, United States
Springfield Diabetes and Endocrine Center
Springfield, Illinois, United States
Medical Research Consortium
Indianapolis, Indiana, United States
Wichita Clinic, PA
Wichita, Kansas, United States
University of KY Internal Medicine
Lexington, Kentucky, United States
Pennington Center
Baton Rouge, Louisiana, United States
JM Clinical Trials, Inc.
Swansea, Massachusetts, United States
Montana Medical Research, LLC
Missoula, Montana, United States
Endocrinology and Diabetes Consultants, PC
Dover, New Hampshire, United States
Radiant Research
Lawrenceville, New Jersey, United States
Lovelace Scientific Resources
Albuquerque, New Mexico, United States
Central New York Clinical Research
Manlius, New York, United States
Comprehensive Weight Control Program
New York, New York, United States
St. Luke's Roosevelt Hospital Center
New York, New York, United States
Center for Nutrition and Preventive Medicine
Charlotte, North Carolina, United States
Multi-Specialty Research Associates of North Carolina
Raleigh, North Carolina, United States
South Dayton Research Associates
Beavercreek, Ohio, United States
Lindner Clinical Trials Center
Cincinnati, Ohio, United States
Radiant Research
Columbus, Ohio, United States
Radiant Research
Portland, Oregon, United States
SFM Clinical Trials
Scotland, Pennsylvania, United States
Radiant Research
Wyomissing, Pennsylvania, United States
ClinSearch
Chattanooga, Tennessee, United States
Clinical Research Associates, Inc
Nashville, Tennessee, United States
Radiant Research
Austin, Texas, United States
Dallas Diabetes and Endocrine Center
Dallas, Texas, United States
nTouch Research
Houston, Texas, United States
Quality Research, Inc.
San Antonio, Texas, United States
Advanced Clinical Research
Salt Lake City, Utah, United States
Commonwealth Clinical Research Specialists (CCRS)
Richmond, Virginia, United States
Rainer Clinical Research Center, Inc.
Renton, Washington, United States
Clinical Nutrition Clinic, University of Wisconsin
Madison, Wisconsin, United States
Corunna Medical Clinic
Corunna, Ontario, Canada
Quarry Family Medicine Clinic
Kingston, Ontario, Canada
Trial Management Group
Richmond Hill, Ontario, Canada
Group North
Windsor, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006 Feb 15;295(7):761-75. doi: 10.1001/jama.295.7.761.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EFC4743
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.